Urinary Incontinence: an overview!! Neil Harris Consultant Urological Surgeon, Leeds
Content 1. Epidemiology of pelvic floor dysfunction Urinary incontinence Bowel dysfunction Sexual dysfunction 2. Treatment options & care pathways 3. Questions!!
Females: spectrum of continence disorders Overactive Bladder SUI Mixed (UUI+SUI) UUI Urgency Frequency Nocturia
Incontinence: other causes
Urinary Incontinence Defn: Involuntary loss of urine Wide range of aetiology Association with pelvic floor dysfunction Wide variety of treatment options Significant unmet need
Urinary incontinence: classification Symptom Description Stress Leakage with physical exertion or on sneezing or coughing Urge Leakage with a strong and urgent desire to void Mixed Combination of stress and urge
Prevalence of OAB in Europe 1 European population-based study of 16,776 males/females aged >40 years: - 17% prevalence of OAB - estimated 5.15 million sufferers in the UK - equates to approx. 50 000 in average one million city! 1. Milsom I et al. BJU International 2001;87:760-766
Prevalence of OAB in different age groups 1 % prevalence 50-40 - men (n=7048) women (n=9728) 41.9 30-20 - 10-3.4 8.7 6.0 10.6 16.9 9.8 11.9 13.2 18.9 16.9 23.7 17.5 22.3 22.1 31.3 0-40-44 45-49 50-54 55-59 60-64 65-69 70-74 75+ Age (years) 1. Adapted from Milsom I et al. BJU International 2001;87:760-766
Impact of OAB on quality of life is greater than that of type 2 diabetes 1 SF-36 score 100-80 - 60-40 - 20-0 - Healthy Diabetes OAB 1. Adapted from Abrams P et al. Am J Managed Care 2000;6(11) Suppl: S580-590 (citing Abrams P, Wein AJ. The Overactive Bladder: A widespread but treatable condition. Stockholm, Sweden, Erik Sparre Medical AB, 1998) SF-36 = Medical Outcomes Study Short Form Health Survey
SUI: Huge unmet need! Vandoninck V BJU Int 2004 46% women incontinent 12% severe QoL significantly compromised 28 31% consulted a physician Similar results from UK study Large unmet need in community!
Incontinence: under-reported Less than half with bladder control problems report it to their health care provider Embarrassment WHY Low expectation for therapy Normal part of aging Availability of absorbent products/pads
Urinary incontinence: QoL issues Role limitation: Toilet mapping Avoidance of exercise/sex Clothing choice Psychological aspects: Fear of leaking / odour Anxiety / depression Loss of self-respect Denial
Stress urinary incontinence: prevalence 48% women of varying age groups suffer from SUI 1 Mean of 11 studies in 11,549 women aged 18 to >60 yrs Urge incontinence Is the complaint of involuntary leakage accompanied by or immediately preceded by urgency 2 Stress incontinence Is the complaint of involuntary leakage on effort or exertion, or on sneezing or coughing 2 Urge Urinary Incontinence 17% Mixed Urinary Incontinence 34% Stress Urinary Incontinence 48% 1. Nitti VW. Rev Urol 2001;3(suppl 1):S2-S6., 2. Abrams P et al. Neurourol Urodynam 2002;21:167-178
Stress Incontinence: aetiology 1 Predispose Gender Race Neurological Muscular Anatomical Collagen Family Induce Childbirth Hysterectomy Vaginal surgery Radical pelvic surgery Radiation Injury Promote Obesity Lung disease Smoking Menopause Constipation Recreation Occupation Medications Infection Decompensate Aging / oestrogen Dementia Debility Disease Environment Medications 1. Bump RC, Norton PA. Obstet Gynecol Clin North Am 1998;25(4):723-746
Diagnosis & Treatment
Diagnosis of Overactive Bladder Most cases of overactive bladder can be diagnosed based on: patient history, symptom assessment physical examination urinalysis Initiation of non-invasive treatment does not require an extensive workup
Physical Examination Rule out possible causes of LUTS Oestrogen deficiency / Atrophic vaginitis Pelvic floor dysfunction Pelvic organ prolapse Exclude other serious pathologic conditions Signs of Hypoestrogenation Prominent caruncle Pelvic organ prolapse compartment grade symptoms Agglutination of labia minora
Incontinence: treatment algorithm Urge incontinence Behavioural changes Physio Drugs Stress incontinence Behavioural changes Physio Drugs Minimally invasive surgery Complex surgery Minimally invasive surgery Complex surgery
Treatment pathway for urinary incontinence in women, based on NICE guidelines Lifestyle interventions Assess and categorise Refer Medication PFE Bladder training Urodynamics ( + other investigations) TVT/ TOT / slings BOTOX / SNS / cystoplasty Assessment Conservative management (including pelvic floor muscle training, bladder training, antimuscarinic treatment) Surgical management
Non-pharmacological therapy: stress & urge incontinence Lifestyle changes Caffeine / alcohol Fluid management Bladder re-training Pelvic floor physio (all have evidence base)
Pharmacologic Therapy for the Treatment of OAB Antimuscarinic agents are the mainstay for treating OAB OAB symptoms relieved by inhibition of involuntary bladder contractions increased bladder capacity Treatment can be limited by side effects such as dry mouth, GI effects (eg, constipation), and CNS effects
Muscarinic Receptor Distribution Dizziness Somnolence Impaired memory and cognition CNS Iris/ciliary body Lacrimal gland Salivary glands Heart Stomach and esophagus Dry mouth Tachycardia Blurred vision Dry eyes Dyspepsia Colon Constipation Bladder (detrusor muscle) Abrams P, Wein AJ. The Overactive Bladder A Widespread and Treatable
Anticholinergics: efficacy solifenacin tolterodine
Antimuscarinics: mainstay of solifenacin (Vesicare ) oxybutynin (Cystrin, Ditropan, Kentera, Lyrinel XL ) propiverine (Detrunorm, Detrunorm XL) treatment of OAB tolterodine (Detrusitol, Detrusitol XL ) trospium (Regurin ) darifenacin (Emselex ) fesoterodine (Toviaz )
Refractory incontinence At least a third of patients failed lifestyle/physio/drugs Need more complex functional evaluation urodynamics Treatment more complicated / expensive invasiveness & morbidity
Failure of conservative Rx - is surgery indicated? Effect on daily life What are precise goals / expectations Improvement or cure Have other treatments really failed PFE, weight loss, cough, bladder drill, medication Counselled appropriately Accept more complex treatment
Botulinum Toxin Produced by Clostridium Botulinum Inhibits release of efferent and afferent neurotransmitters Used in 1980s (ophthalmology) Wide range of applications in urology Detrusor Overactivity (IDO, NDO) DSD Pain syndromes / PBS
Sacral neuromodulation Increasing indications and usage Mechanism not fully understood alteration of afferent and efferent reflexes Now considered as first line in refractory DO NICE Neurogenic and nonneurogenic voiding dysfunction / pain
Very expensive Requires motivation / technical ability probably the best option
Major surgery Rarely indicated neurogenic / poor bladder compliance Ileocystoplasty / detrusor myomectomy/ urinary diversion Major surgery initial morbidity long term No better than BOTOX / SNS
Ileocystoplasty CLAM
Refractory stress incontinence Half of all patients Usually minimally invasive surgery Not all will desire treatment Few will need repeat / complex surgery
SUI: surgical management Drugs Bio-Injectables Midurethral slings Synthetic Autologous Colposuspension Artificial Sphincter Consider need for prolapse repair
Stress Incontinence: primary procedure Synthetic midurethral sling TVT / TOT / TVT-O etc... Placed tension free Seems to be as effective as colposuspension Well defined, but SMALL risks Failure Erosion Urinary Retention OAB / DO
TVT success Hilton P Am J Obstet Gynecol 2004 n=344 randomized TVT / colpo TVT: 83% objectively cured @ 2 years Similar to colpo
Failures! Live with symptoms Further surgery BUT may be worse! Redo Augment with bulking agents Fascial sling AUS Urinary Diversion
Urinary incontinence: summary Common pelvic floor dysfunction Underdiagnosed QoL Treatable many simple some complex